Reviewer's report

Title: The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.

Version: 1 Date: 28 May 2009

Reviewer: Eric von Hofe

Reviewer's report:

Discretionary Revisions

1. In the results section of the Abstract, second sentence should read “When immunized Balb/c and HHD….

2. Indicate in the Conclusion of the Abstract that specific cellular and humoral responses were observed as well as efficacy.

3. In the Background section, second sentence of second paragraph should read “…is also observed in various other human cancers……

4. In the Background section, fifth to last sentence, it is indicated that ECD/Her2 is used for ‘tumor prevention’. Perhaps it would be more accurate to say ‘…to reduce tumor growth’.

5. In the Results section, the first paragraph seems to repeat some of the information already presented in the Methods section.

6. It would be very helpful if the numbers of mice in all the experiments was given.

7. SK-BR-3 cells are used to check for antibodies, though D2F2/E2 or wild-type D2F2 are used for in vivo study – why?

8. Similar to 7., it would be of interest to see the activity of CD8+ T cells from immunized mice against wild-type D2F2 cells.

9. Similar to 7. and 8., it would be good to know something about the growth of non-transfected ALC cells in immunized HHD mice.

10. Given the different cell types used, it is not entirely clear why the authors focus on the importance of CTL activation at the end of the discussion. A few more words of explanation might be helpful.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests